Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.64 |
| ▸ | FLT1 | P17948 | 7/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.64 |
| ▸ | KIT | P10721 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | HLA-A | P04439 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | FRK | P42685 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14267795 | 0.87 | FLT1 (0.63) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1651296 | 0.85 | FLT1 (0.79) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL14267794 | 0.81 | FLT1 (0.65) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL5753555 | 0.80 | FLT1 (0.80) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1386339 | 0.79 | KDR (0.48) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1652660 | 0.79 | KDR (0.69) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL1652015 | 0.78 | FLT1 (0.55) | KDRFLT1PDGFRBKITMEN1 | |
| Hydrochloric Acid SCHEMBL6609546 | 0.77 | KDR (0.98) | KDRFLT1PDGFRBKITCIT | |
| SCHEMBL13955418 | 0.76 | KDR (0.52) | KDRFLT1PDGFRBKITMEN1 | |
| SCHEMBL5754939 | 0.75 | KDR (0.65) | KDRFLT1PDGFRBKITMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4673977-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | claimed |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2005-08-11 | — | — | US | claimed |
| US-6911440-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-06-28 | — | — | US | claimed |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2004-07-22 | — | — | US | claimed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | claimed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | claimed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| US-20150099803-A1 | VETERINARY USE OF DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, AND DIBROMODULCITOL TO TREAT MALIGNANCIES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-04-09 | — | — | US | disclosed |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2014194312-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRIAN TUMOR | DEL MAR PHARMACEUTICALS (CA) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | KDR 3803/4885FLT1 3556/4885PDGFRB 4079/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | KDR 3803/4885FLT1 3556/4885PDGFRB 4079/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | KDR 3803/4885FLT1 3556/4885PDGFRB 4079/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | KDR 3684/4885FLT1 2286/4885PDGFRB 4517/4885 |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | KDR 2/4885FLT1 1/4885PDGFRB 65/4885 |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, FLT1, TIE1 | KDR 1/4885FLT1 2/4885PDGFRB 41/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | KDR 3803/4885FLT1 3556/4885PDGFRB 4079/4885 |
| US-20150099803-A1 | VETERINARY USE OF DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, AND DIBROMODULCITOL TO TREAT MALIGNANCIES | DAD1, DDOST, DERA | KDR 2225/4885FLT1 1652/4885PDGFRB 4323/4885 |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, FLT4, KDR | KDR 3/4885FLT1 1/4885PDGFRB 77/4885 |
| US-20150087687-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | CYP7A1, CYP3A7, UGT2B7 | KDR 3908/4885FLT1 2634/4885PDGFRB 3482/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | KDR 1640/4885FLT1 1351/4885PDGFRB 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.